Oxford Lymphoid Disorders Study Group
- Blood Cancer
The Oxford Lymphoid Disorders Study Group (OLDSG) was launched in September 2020, and brings together a network of researchers and clinicians from across the University of Oxford and Oxford University Hospitals Trust.
At present, around 3-4% of people will develop either lymphoma or Chronic Lymphocytic Leukaemia (CLL) during their lifetime. Together, lymphoma and CLL represent the commonest blood cancer by some margin.
The purpose of OLDSG is to:
- to increase the visibility of lymphoid disorder research in the university
- to foster collaborations between clinicians and laboratory-based scientists leading to high quality translational projects
- to interact with patients and the public at all levels of project development to deliver research which impacts directly on patient need
Group members work on a range of issues relating to lymphoid disorders, haematology, immunology, molecular diagnostics and late effects research.
Group members
-
Graham Collins
Haematologist and Group Chair
-
Toby Eyre
Haematologist
-
David Cutter
Radiotherapist and Epidemiologist
-
Gareth Turner
Pathologist
-
Mariolina Salio
Immunologist
-
Anna Schuh
Molecular Diagnostics and Chronic Lymphocytic Leukemia lead
-
Brian Nicholson
Primary Care Physician and Early Detection
-
Penny Clark
Patient Representitive
BLOOD CANCER NEWS
Researchers provide a perspective on mapping the bone marrow using new spatial transcriptomic technologies
14 December 2024
RDM researchers have outlined the potential benefits and limitations of new spatial transcriptomic technologies for mapping the bone marrow in patients with blood cancer.
Researchers develop new tool to better predict AML outcomes in older patients
17 September 2024
In a study published in the Journal of Clinical Oncology, an international research team has used machine learning to improve risk stratification for patients over 60 diagnosed with acute myeloid leukaemia, an aggressive type of blood cancer.